Moving closer to people with allergy
|
|
- Ernest Andrews
- 5 years ago
- Views:
Transcription
1 Moving closer to people with allergy Investor Relations Presentation January I Investor Relations Presentation January 2017
2 ALK: Towards redefining treatment of severe allergies The commercial leader and foremost innovator in Allergy Immunotherapy (AIT) ALK fundamentals AIT: A unique disease-modifying treatment for people with severe allergies Global reach Exclusivity via high-quality biological manufacturing processes including sourcing and standardisation of allergens 2,300 employees (+200 in 2016) Patient solutions in all areas of AIT SLIT-tablets Diagnostics, adrenaline 2016 outlook Revenue > DKK 2.9b SCIT (injections) SLIT-drops Today ~80% Europe 99% allergy-related Niche ~1.5m patients Strategic drivers Globalisation of AIT Standardised, evidence-based products Prescriber expansion Asthma treatment and prevention Future Truly global Allergy & asthma Mainstream for people with severe allergies 2 I Investor Relations Presentation January 2017
3 Re-educating the immune system Allergy Immunotherapy (AIT) AIT Treatment with standardised doses of allergens (proteins) Disease modification: Treats the cause of allergy in addition to reducing symptoms and use of other medications Typically recommended for three years Common causes of allergic rhinitis with/without conjunctivitis Other allergy sources House dust mite Grass Tree pollen Ragweed Japanese cedar Insects Food Prevalence: 10-30% globally, most common chronic disease 30-60% of patients with allergic rhinitis develop allergic asthma 3 I Investor Relations Presentation January 2017
4 Strategic direction Market access GMP compliance Mix of trusted and newer products Transform Expand Asthma New prescribers Asthma New markets Strategic intent From a European company focused on allergic rhinitis to a global company with standardised, evidence-based products which also treat and potentially prevent asthma. 4 I Investor Relations Presentation January 2017
5 Global footprint Partnership to leverage growth SLIT-tablets SLIT-tablets and SCIT EUR ~10 billion Global allergic rhinitis market EUR ~1 billion Global AIT market International; 10% North America; 15% Europe; 75% International; 8% ALK sales 2015 North America; 17% Europe; 75% ACARIZAX SLIT-tablets AIT treatment is mainly distributed as finished products in Europe and recently also in the USA and International markets - in North America, also as bulk extracts to allergy specialists 5 I Investor Relations Presentation January 2017
6 Financial overview DKK million E 9M M15 1) Base business 2,145 2,219 2,384 ~25% 2, % SLIT-tablet partnerships 2) N.A. 68 Revenue 2,244 2,433 2,569 ~3,000 2, % (Revenue in USDm) Gross margin 69% 70% 67% < 67% 68% R&D ~400m 282 (% of revenue) 21% 16% 16% - 13% S, M & A , EBITDA before special items and excl. milestones /royalties % EBITDA before special items > (in USDm) CAPEX ~ Free cash flow (85) N.A. 198 Equity ratio 69% 69% 63% - 62% Cash and marketable securities ) Growth in local currencies 2) Revenue from SLIT-tablet partnerships in North America and International markets. In years , this mainly consists of milestones and service fees. 6 I Investor Relations Presentation January 2017
7 The markets: Europe Growth rates are stated as organic growth in local currencies Q3: 20% growth DKK 500m revenue (428) Benefits from market disruptions in Q1-Q2 Market share gains in several markets Base business growth +20% 60% 40% High double-digit growth in tablet and SLIT-drops sales; declining SCIT sales Germany main market affected by production upgrades Q3-15 Q4-15 Q1-16 Q2-16 Q3-16 Revenue Growth rate 20% 0% ALK s strategy Grow base business profitability and optimise product portfolio Lead transition to evidence-based products Use ACARIZAX as catalyst for improving patient access Develop and launch tree SLIT-tablet +51% +63% 7 I Investor Relations Presentation January 2017
8 The markets: North America Growth rates are stated as organic growth in local currencies Q3: Total revenue up 6% to DKK 119m (113) 11% growth in base business Allergen extracts (SCIT), diagnostics, etc. Adverse impact of SCIT production update MSD partnership ended Two acquisitions completed in December 2016 Effective from 3 January 2017 DKKm Base business growth +11% Q3-15 Q4-15 Q1-16 Q2-16 Q3-16 Revenue Growth rate 20% 10% 0% USD 15m in additional revenue ALK s strategy 11% growth in base business Sales of allergen extracts to allergists Allergen extracts (SCIT), diagnostics, etc. Repatriate SLIT-tablets and complete registrations Transfer knowledge and insights, ~50 new employees Develop long-term business model 8 I Investor Relations Presentation January 2017
9 Reshaping Product Supply for future growth SLIT-drops: Capacity expansion H1 2016: Capacity doubled H2 2016: Additional staff to meet demand Market leadership in France to be retained SCIT: Compliance/ production upgrades Response to high demand and increasing regulatory requirements Temporary reduction of capacity and prolonged delivery times for certain products and markets DKK m impact on sales in 2016 SLIT-tablets: Capacity expansion Expansion of Source Materials capacity Scale to global roll-out of ACARIZAX Scale to roll-out of tree SLIT-tablet Multiple auxiliary systems 9 I Investor Relations Presentation January 2017
10 Pipeline is key for ALK s global expansion Product GRAZAX Grass ARC GRAZAX Asthma prevention ACARIZAX HDM rhinitis/asthma Tree SLIT-tablet Tree ARC GRASTEK * Grass ARC RAGWITEK TM * Ragweed ARC HDM SLIT-tablet* HDM rhinitis Pre-clinical Phase I Phase II Phase III Filing Marketed 2016 TBC*** MITICURE ** HDM rhinitis 2015 Japanese cedar SLIT-tablet Cedar pollen ARC ACARIZAX **** HDM rhinitis/asthma GRAZAX **** Grass ARC Ragweed SLIT-tablet**** Ragweed ARC ARC: allergic rhinoconjunctivitis HDM: house dust mites *) Licensed to Merck for North America **) Licensed to Torii for Japan ***) To be communicated ****) Licensed to Abbott/Seqirus 10 I Investor Relations Presentation January 2017
11 Update on ACARIZAX globalisation No 1 in DE & DK FDA pre-approval inspection Uptake progressing Four new filings Official launch in Q3 Launched Approved Filed Preparations for filing 11 I Investor Relations Presentation January 2017 * ACARIZAX is the trade name for ALK s HDM SLIT-tablet in Europe
12 Major future pipeline events Pivotal news-flow concerning all five SLIT-tablets Region Event Exp. timing Europe Completion of Phase III trial with tree SLIT-tablet Additional launches of ACARIZAX Initiation of paediatric development of ACARIZAX ff 2017 USA Canada Review of BLA for ACARIZAX 2017 Review of NDA for ACARIZAX 2017 Japan Phase III trial with MITICURE in paediatric patients Approval of Japanese cedar SLIT-tablet Russia Approvals of GRAZAX and ragweed SLIT-tablet 2017 Regulatory filing of ACARIZAX 2016/17 Australia Approval of GRAZAX 2016/17 Rest of world ACARIZAX : Filings/approvals in South East Asia; Approval in Turkey 2016/17 12 I Investor Relations Presentation January 2017
13 Thank you for your attention Read more: Investor Relations: Per Plotnikof Head of Investor Relations Phone: I Investor Relations Presentation January 2017
14 APPENDIX 14 I Investor Relations Presentation January 2017
15 Europe: A market in transition Europe: Market profile Mature, diverse markets under regulatory transformation 40% 30% 30% 34% ~1.3m patients on AIT Mainly legacy and named-patient products Restricted market access 30% France Others Germany 36% ALK Others Stallergenes SLIT-tablets fully-documented and registered Main allergies: HDM, Grass and Tree ~EUR 675m total industry sales (2015) 15 I Investor Relations Presentation January 2017
16 North America: A significant opportunity USA: Market profile Self-mixing and compounding of SCIT by allergists common >6m severe patients eligible for AIT SCIT: low take-up and high drop-out rate 50% refuse treatment, 84% drop out 45% 30% 25% ALK Others Greer ~2.5m patients on AIT USD 2-3bn Billing to insurance USD 150m industry revenue (2015) Main allergies: HDM, Grass, Ragweed and Tree 16 I Investor Relations Presentation January 2017
17 Japan: A new opportunity Japan: Market profile Allergy prevalence higher than EU and USA AIT currently almost non-existent as a treatment option Japan: ALK s strategy Partnership with Torii MITICURE launched in December 2015 for treatment of HDM allergic rhinitis Positive Phase II/III results from cedar SLIT-tablet in August 2015, registration application submitted in December 2015 SCIT HDM licensed for market-building Main allergies: HDM and Japanese cedar 17 I Investor Relations Presentation January 2017
18 ACARIZAX for allergic rhinitis and allergic asthma First product for both indications In Europe, ACARIZAX is indicated in adults (18-65 years) diagnosed by clinical history and positive test of HDM sensitisation, with at least one of the following conditions: Persistent moderate to severe HDM allergic rhinitis despite the use of symptom-relieving medication HDM allergic asthma which is not well controlled by inhaled corticosteroids and is associated with mild to severe HDM allergic rhinitis and where patients' asthma status has been carefully evaluated In Japan, ACARIZAX under the name MITICURE is indicated for the treatment of allergic rhinitis caused by HDM in adults and adolescents (12-64 years). 18 I Investor Relations Presentation January 2017
19 ACARIZAX for the most common allergy Allergic rhinitis (hay fever) is the most common childhood allergy; allergic asthma is the most common chronic lower respiratory disease in children The link between house dust mite (HDM) induced allergic rhinitis and asthma: Allergic asthma and allergic rhinitis frequently co-exist in the same person ~50% of HDM allergic rhinitis patients also suffer from allergic asthma ~50% of asthmatic patients are reported to be sensitised to HDM HDM-allergic patients risk of developing asthma is significantly higher than that of other allergy patients 19 I Investor Relations Presentation January 2017
20 Best documented AIT product ACARIZAX : Approved for allergic rhinitis and allergic asthma in Europe Asthma results (MT04) published in JAMA* in April 2016 ACARIZAX works by addressing the cause of the respiratory disease Reduces days impacted by severe allergic rhinitis symptoms by 50% ACARIZAX furthermore offers better asthma control Reduces the risk of moderate to severe asthma exacerbations by 34% Reduces risk of nocturnal awakenings by 36% * Journal of the American Medical Association 20 I Investor Relations Presentation January 2017
21 The unmet medical need in Europe ACARIZAX for patients not well-controlled with symptom relieving medication HDM respiratory allergy sufferers ~35m adults and ~9m children and adolescents Potential HDM AIT-eligible patients* ~3m adults and ~1m children Approximately 50% have access to AIT ~1.5m adults and ~0.5m children Patients currently treated with AIT ,000 patients, DKK bn industry sales * Moderate-severe, not well-controlled patients 21 I Investor Relations Presentation January 2017
22 GRAZAX Asthma Prevention (GAP) trial Initiated in 2009, completed in 2016 First large, multinational placebo-controlled trial with AIT (GRAZAX ) in asthma prevention 812 children with grass pollen allergy, but no signs of asthma Three years with daily intake of GRAZAX or placebo; Twoyear follow-up to monitor effects post-treatment Objective: To investigate the effect of GRAZAX on children s risk of developing asthma Top-line results Significant reduction in proportion of children experiencing asthma symptoms or using asthma medication; effect sustained two years after treatment Significant reduction of allergic rhinoconjunctivitis symptoms; effect sustained two years after treatment GRAZAX disease-modifying effect confirmed *: p<0.05 **: p<0.01 Placebo GRAZAX The trial showed no effect in terms of time to first diagnosis of reversible impairment of lung function. 22 I Investor Relations Presentation January 2017
23 Sponsored ADR Programme ALK has a sponsered Level l ADR programme in the USA. The ADRs trade on Over-The-Counter ( OTC ) market in the USA. Details are as follows: Ticker Symbol: AKABY CUSIP: Ratio: 5 ADR : 1 Ordinary Share ADR depositary: Deutsche Bank Share price information: Please contact the Deutsche Bank s dedicated ADR broker desks: Jay Berman (New York) Simon Davies (London) Tel: Tel: jay.x.berman@db.com simon.davies@db.com 23 I Investor Relations Presentation January 2017
24 ALK Equity and shareholder structure ALK (ALK B) listed on NASDAQ Copenhagen (Reuters: ALKB.CO / Bloomberg: ALKB.DC) Number of shares outstanding: 10.1m Two share classes (A / B) Market Cap: ~EUR 1.2bn Largest shareholder groups: Lundbeck Foundation (40%), since 1987 ATP, Danish Labour Market Pension Fund (>5%) Jupiter Asset Management, Ltd. (>5%) ~13,000 retail investors (~25%) 24 I Investor Relations Presentation January 2017
25 Forward-looking statements This presentation contains forward-looking statements, including forecasts of future revenue and operating profit, as well as expected business-related events. Such statements are subject to risks and uncertainties as various factors, some of which are beyond ALK s control, may cause actual results and performance to differ materially from the forecasts made in this presentation. Without being exhaustive, such factors include general economic and business-related conditions including legal issues, uncertainty relating to demand, pricing, reimbursement rules, partners plans and forecasts, fluctuations in exchange rates, reliance on suppliers, as well as changes to market structures. An additional factor would be the consequences of potential side effects from the use of ALK s products, as allergy immunotherapy may be associated with allergic reactions of differing extents, duration and severity. 25 I Investor Relations Presentation January 2017
A world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations Presentation April 2017 1 I Investor Relations presentation April 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationA world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP
A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy General Investor Presentation February 2016 1 I ALK at a glance Commercial leader and foremost innovator within respiratory diseases World leader in allergy immunotherapy
More informationLeading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products
ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationThe leading allergy specialist with a history dating back to 1923
The leading allergy specialist with a history dating back to 1923 7% 4 year CAGR 11% 4 year CAGR 33% of global allergy immunotherapy market 2012 Revenue: DKK 2.35b (EUR 314m) 2012 EBITDA: DKK 306m (EUR
More informationALK at a glance The leading allergy specialist
ALK at a glance The leading allergy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise tablet portfolio Modern allergy
More informationWe improve quality of life by preventing and curing allergy
We improve quality of life by preventing and curing allergy SEB Enskilda Nordic Small & Mid Cap Seminar 2008 Jens Bager, President & CEO ALK-Abelló a fast growing pharmaceutical company Global pharmaceutical
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationALK-Abelló A/S. Click View,Header and Footer to change this text to filename and department name
ALK-Abelló A/S June 25, 2008 Click View,Header and Footer to change this text to filename and department name 1 Changing the way we treat allergy Piper Jaffray 19th Annual Health Care Conference, New York
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy R&D and Business Briefing New York, May 2014 ALK s equity story An emerging speciality pharma with a global growth strategy Jens Bager President and CEO Today s
More informationAllergy Therapeutics. Corporate Presentation. Proactive Investors 28th January 2016 Ian Postlethwaite, Finance Director
Allergy Therapeutics Corporate Presentation January 2016 Introduction We treat people with Allergic disorders Focused on the moderate to severe patients Providing treatments that cure the disease, not
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationA world leader in allergy immunotherapy
A world leader in allergy Milestones in the history of ALK ALK was founded on 9th June 1923 when pharmacist Peter Barfod and physician Kaj Baagøe recorded the first pharmaceutically manufactured allergy
More informationALK-Abelló Research & Development. Henrik Jacobi MD, EVP Research & Development
ALK-Abelló Research & Development Henrik Jacobi MD, EVP Research & Development Agenda Latest news on GRAZAX 3rd year data from long-term study (GT-08) Effect on asthma symptoms in children (GT-12) Status:
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy R&D and Business Briefing New York, May 2014 ALK R&D and Business Briefing Agenda 13.00: ALK An emerging speciality pharma company with a global growth strategy
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationSlide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationVery good Q3 contribution from Vegetable Juices Inc.
2014 nine-month sales (1 st January to 30 September 2014) Very good Q3 contribution from Vegetable Juices Inc. Worldwide economic environment still adverse Sustained growth by Food & Beverage Press release
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationTHE NEXT GROWTH PHASE
THE NEXT GROWTH PHASE Investor Briefing Non-Deal Roadshow March 2019 Melbourne Sydney CLINUVEL PHARMACEUTICALS LTD Darren Keamy, Chief Financial Officer Malcolm Bull, Investor Relations Manager ASX: CUV
More informationForward Looking Statements
Therapeutic products for respiratory diseases September 2008 Forward Looking Statements This presentation may contain forward-looking statements that are based on management s current expectations and
More informationMore information at
Report Information More information at https://www.htfmarketreport.com/reports/1288313 Global Homeopathic Products Market Professional Survey Report 2018 Report Code: HTF1288313 Pages: 111 Price: 1-User
More informationPresentation First quarter 2006
Immunity for Life TM Presentation First quarter 2006 CEO Gunnar Rørstad CFO Finn Samuelsen 10 May 2006 Highlights - operations Inclusion of patients almost completed in the the phase II clinical trial
More informationColoplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationZealand Pharma A/S Interim report for Q (un-audited)
Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and
More informationNordea investor meeting. June 18 th, 2018 Kristian Villumsen, EVP Chronic Care
Nordea investor meeting June 18 th, 2018 Kristian Villumsen, EVP Chronic Care Chronic Care represents more than 75% of Coloplast sales and we continue to outgrow the market FY 15/16 Chronic Care Rest of
More informationLeading Intimate Healthcare
21 May 2008 1 Leading Intimate Healthcare Investor presentation H1 2007/08 2 Agenda Introduction to Coloplast First 6 months 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Immunotherapy Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Immunotherapy Agents Prime Therapeutics will review Prior Authorization
More informationGlobal Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023
Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Psoriasis Pipeline Drugs Industry Sizing, Growth and Forecast
More informationThe Future of Allergy Treatment Ultra-Fast Allergy Immunotherapy
The Future of Allergy Treatment Ultra-Fast Allergy Immunotherapy 1 Anergis Focus on Allergy Immunotherapy (AIT) High Medical Need and Patient Demand 500 M allergic patients - fastest growing chronic condition
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationNestlé Investor Seminar 2008
Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationFor personal use only. Investor Briefing. Bayswater, 1 st December 2016
Investor Briefing Bayswater, 1 st December 2016 Introduction Samantha Cheetham Chief Executive Officer To be an innovative leader in the dental industry, developing our people and partnering with dentists
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationBariatric Surgery Devices - North America Analysis and Market Forecasts
Bariatric Surgery Devices - North America Analysis and Market Forecasts Bariatric Surgery Devices - North America Analysis and Market Forecasts BioPortfolio has been marketing business and market research
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationPartnering for Growth
Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationTherapeutic products for respiratory and autoimmune diseases. Annual General Meeting
Therapeutic products for respiratory and autoimmune diseases Annual General Meeting November 2007 Summary Objective Lead products Discovery Listings Location Facility Employees Cash (30/6/07) Shares outstanding
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationCorporate presentation January A new generation of allergy immunotherapies
Corporate presentation January 2015 A new generation of allergy immunotherapies Disclaimer Neither this presentation nor any verbal communication shall constitute, or form part of, any offer, invitation
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationNew Merck Pipeline. Combined Legacy Merck and Schering-Plough Research Pipelines
New Merck Pipeline Combined Legacy Merck and Schering-Plough Research Pipelines November 4, 2009 Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined
More informationMore than half to 50 million 5th 3rd
Did you know? More than half (54.6%) of all U.S. citizens test positive to one or more allergens. Allergic diseases affect as many as 40 to 50 million Americans, including asthma and bronchitis. Allergies
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationSecondary prevention of allergic disease. Dr Adam Fox United Kingdom
Secondary prevention of allergic disease Dr Adam Fox United Kingdom Disclosures Lecture fees: Danone, Mead Johnson, ALK-Abello, Stallergenes, Allergy Therapeutics Industry-sponsored grant: Danone, ALK-Abello
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationHIGH CLINICAL ACCEPTANCE OF METVIX PDT
HIGH CLINICAL ACCEPTANCE OF METVIX PDT PhotoCure ASA Second Quarter Report 2002 Highlights: Marketing of Metvix PDT in Europe Progressing as Planned Positive Phase III Clinical Results in the Treatment
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationLifeCycle Pharma A/S. 5 th Swiss-Scandinavian Bio-Business Seminar 2009 October 1, Peter Schøtt Knudsen, Head of IR & Legal
LifeCycle Pharma A/S 5 th Swiss-Scandinavian Bio-Business Seminar 2009 October 1, 2009 Peter Schøtt Knudsen, Head of IR & Legal FORWARD LOOKING STATEMENTS This presentation contains forward looking statements.
More information